

**Table S3.** Additional therapies, by intention-to-treat analysis

<b>Characteristic</b>	<b>Intervention n=51</b>	<b>Control n=44</b>	<b>P-value</b>
<b><i>Hormonal contraception</i></b>			
OC with monthly bleeding	2 (4.2%)	3 (7.3%)	
<u>Levonorgestrel</u> IUD	5 (10.4%)	3 (7.3%)	
Contraception continuously *	3 (6.3%)	3 (7.3%)	
Total hormonal additional treatment	10 (20.8%)	9 (22.0%)	0.99
<b><i>Surgical additional treatment</i></b>			
Hysteroscopic niche resection	0	9 (22.0%)	
Endometrium ablation	0	2 (4.9%)	
Transcervical resection fibroid	0	1 (2.4%)	
Total laparoscopic hysterectomy	0	1 (2.4%)	
Total surgical interventions	0	13 (31.7%)	<b>&lt; 0.01</b>
Total surgical interventions (without hysteroscopic niche resection)	0	4 (9.8%)	0.05

Data are reported as 'n (valid percentage)' or as 'median (IQR)'. Analyses are by intention to treat.

\* Contraception continuously = Continuous use of oral contraception, Depot provera or GnRh agonist